Affordable Access

deepdyve-link
Publisher Website

Markers of hepatic fibrosis.

Authors
  • Caballería, Llorenç1
  • Torán, Pere2
  • Caballería, Joan3
  • 1 Unitat de Suport a la Recerca Metropolitana Nord, Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Mataró, Barcelona, España; Servei d'Hepatologia, Hospital Clínic, Barcelona, España. Electronic address: [email protected]
  • 2 Unitat de Suport a la Recerca Metropolitana Nord, Institut Universitari d'Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Mataró, Barcelona, España; Servei d'Hepatologia, Hospital Clínic, Barcelona, España.
  • 3 Servei d'Hepatologia, Hospital Clínic, Barcelona, España; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), España.
Type
Published Article
Journal
Medicina Clínica
Publisher
Elsevier
Publication Date
Oct 18, 2017
Identifiers
DOI: 10.1016/j.medcli.2017.08.009
PMID: 29055492
Source
Medline
Keywords
License
Unknown

Abstract

Chronic liver diseases constitute a major health problem. Chronic liver inflammation, defined by the degree of hepatic fibrosis, is asymptomatic in a significant percentage of patients; hence, the disease often remains undiagnosed until it has reached very advanced phases and, frequently, when the damage is irreversible. Ideally, patients should be screened during the initial phases of chronic inflammation, thus allowing for the effective management of the natural evolution of the disease by stopping or delaying its course. Standard diagnostic methods (transaminase determination or abdominal ultrasonography) do not allow for the early diagnosis of the degree of fibrosis. A liver biopsy is the invasive method of choice to screen for fibrosis, however, due to its limitations, non-invasive diagnostic methods such as elastography or serological markers are increasingly used as a good alternative for the early diagnosis of the degree of fibrosis.

Report this publication

Statistics

Seen <100 times